Royalty Pharma plc revenue by segment RPRX

Annual Quarterly

Royalty Pharma plc splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Financial Royalty Assets at $2.3 billion, 95% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020
Revenue	2,617	2,378	2,264	2,355	2,237	2,289	2,122
Financial Royalty Assets	2,473 +10.9% share 94.5%	2,261 +5.2% share 95.1%	2,149 -2.2% share 95.0%	2,198 +3.4% share 93.3%	2,125 +2.9% share 95.0%	2,065 +5.4% share 90.2%	1,960 share 92.3%
Royalty Income Other	144 +20.5% share 5.5%	117 +2.5% share 4.9%	114 -27.2% share 5.0%	157 +110.1% share 6.7%	75 +40.5% share 3.3%	53 +179.7% share 2.3%	19 share 0.9%
Intangible Royalty Assets	—	—	—	1 -97.8% share 0.0%	37 -78.1% share 1.7%	171 +19.4% share 7.5%	143 share 6.8%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: RPRX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: United Kingdom
Headquarters: New York, NY
SEC filer status: Large accelerated filer
SEC CIK: 1802768

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.